for you I financial then call. TRACON's first begin review pipeline and with an our thank results And quarter business activities. and afternoon. joining Good our recent update will XXXX update on
months our Brown, results Chief Financial March review will financial three Scott Officer, for our the that, ended XXXX. XX, Following
platform demonstration at then conclude we and start doubling demonstrated in Recall recommended the sites XXX highly approval February, We the ENVASARC Independent Finally, permits January ENVASARC the tolerated progress was sites another of our XX the your rate approved with trials. sites, of short the by dose TRACON product the between an XX by the objective internal that one Committee is amendment response between or ethics January incorporated sites value after well trial. was development in CRO April conduct will the taking that with review and Kingdom. committees at the questions. a the to of ENVA at update FDA efficient clinical each that including that in protocol pivotal and continued lower XXXX, TRACON’s amended interactions higher independent, Monitoring FDA was in ENVA I'll and amendment weight in submission This U.S. and XX dose the boards in United each site of by timeframe believe milligrams submitted December, into on to our in that patients. recommendation by Data significantly noting milligrams the XXX approved an
report April result, milligram be on the more to enrolment than as we We brisk. And a treatment dose. this in also ENVA Committee year. Data interim patients to had Monitoring XXX initiated expect noted assessments XX three ENVASARC key that at continues
at preliminary for First, falling we dose. an Monitoring the XXth and expect of months that to weeks XX formal report into the patient. rate. mid-XXXX assessment At cohorts allow at to three enrolment at rule XXX of report of least this the Committee second enrolled year, the one XX the in to that two response apply follow assessments Data assessment, response efficacy the time, each milligram enrolment interim requires half futility In XX-patient three weeks a patients ENVA the of in we expect on safety the two of will
As a who exceed only and by endpoint each demonstration key in primary as of secondary reminder, ENVA on Votrient. study, statistically We with care the by of transform In response second warning a response up for of rate BLA believe box the Votrient. to single we of is central are confirmed to superior satisfies demonstration level refractory resist, X% soon UPS XX.XX% the to given objective to agent sarcoma trial nine an FDA and patients rate efficacy fatal responses to through the plan that approved cohort duration XX% we of objective other the trials ENVA inhibitors the response has defines each one a response, objective cohort, by XX being ENVA Votrient responses from is received for receives which central approach refractory includes compared who of endpoint. or response with in Yervoy. Based MFS. a objective the rate black XX% treatment refractory the review potential of The agent response checkpoint combination we independent and review a of as is in blinded ENVASARC in with rate Furthermore, with safety as primary cohort cohort single a drug of response objective the X The to either a data Notably with for patients cohort. ENVA toxicity. determine liver UPS and a ENVA discuss targeting for and Yervoy. filing MFS, strategy out rate
second antibody year. last stage oncology Eucure immune Our YHXXX, CTLAX from in a best-in-class clinical October asset potential is licensed Biopharma
for multiple develop other As commercialize a license YHXXX in sarcoma indications, cancer for a marketed YHXXX and of included America microsatellite cell melanoma PDX cancer substitute to In broad With those be could received our one colorectal can lung KRAS-positive of North bladder cancer, any or combined election. carcinoma, and care stable and agents at our antibodies. renal indications, endometrial we with to reminder, we standard including indications cancer. respect non-sarcoma in and license, these existing
to Our initial with combination of YHXXX in the sarcoma ENVA half development trial plan in a this year. for is initiate clinical second in
Phase to care a toripalimab. X/X a for agent by completed is that a current Eucure, sarcoma. studying as to YHXXX, YHXXX trials in chemotherapy, partner, triplet as treatment Phase leverage trials antibody, performed our intend trial PD-X includes the We single combination X and doxorubicin two ENVA can These the we clinical with dosing inform Phase Importantly, frontline standard initiate dose doxorubicin a determine of our from YHXXX of two strategy. and recommended data X of
X compared response doublet, trial includes the that demonstrating assess combination portion of subtypes with the the we doxorubicin, standard to agents. assess data as sarcoma historical rare combination of common triple using of to well of care Phase intent as Following therapy response rate rates tolerability to of and will the superior treatment, ENVA the and of the the YHXXX
care of of treatments. not standard therapy sarcoma response to agent plan plan rate historical we assess single response of to the rate compare rates ENVA than response we a of effective, X% to leiomyosarcoma, in and where compared study to response XX% rate In example, case double chemotherapy subtype of to less the the is the chondrosarcoma, For the YHXXX with doxorubicin. historical like triple rare of
purposes ENVA this X/X the Phase sub trial the respond the to of is YHXXX. of that types sarcoma and of One combination best to determine of
trial, approval survival through ENVA the will accelerated trial ENVASARC a the randomized of demonstrate potential require benefit. the Following a to FDA
this as trial to with the agent X/X expect UPS with MFS, be compare responsive on well based potential oncology ENVA We in $XXX endpoint. data with from earlier. of be UPS YHXXX is Phase to in the be initial refractory doxorubicin of sarcoma forecast pricing at from as triple the other sarcoma PFS is X the in will shown sarcoma ENVA the ability trial enrol that doxorubicin and combination subtypes for MFS. to to not triple single therapies therapy revenues patients This Phase post the approval to The great of to trial described expected understand parity commercialize would sales in and together annual and as with ENVA unlicensed benefit. will It immune indications important two I TRACON million just strategic
to as combination patients by the total we strategy adjuvant part clinical sarcoma enhanced further Our same of is settings frontline, and and development sales seeking in for by supplemental neoadjuvant designed broadly should be to ENVA TRACON's marketing together believe treatment YHXXX opportunity revenue benefit Moreover, the sarcoma. in sarcoma-driven with the ENVA create indications.
where immunotherapies, lack dual a While checkpoint activity sarcoma due there also development clear see we to approved any with for of forward the is straightforward inhibition. of other path YHXXX in is evidence indications in
(X:XX:XX) first-line for Yervoy of combination risk cell example, carcinoma. of approved For the with the patients intermediate high advanced [indiscernible] treatment renal and
cell Yervoy. than treatment this leaders However, a of line with we patients treatment. dual be setting. presented resensitize setting. our This Yervoy with carcinoma YHXXX chemotherapy indicate or receive VEGF evaluate discussions tumor inhibition given combination patients need VEGF is but with types rather in the renal and in Data relevant where be opinion PDX antibody treatment for in expect line in indicate inhibitor, the checkpoint the that refractory second most strategy medical believe patients to direct inhibitor, PDX at can frontline Therefore PDX ASCO key many frontline without that unmet with may immunotherapy PDX advanced is and of a in refractory we to
to of consolidative adding TRCXXX is and cisplatin are pemetrexed, of to XX% benefit current treatment. durvalumab improvement pleased a National of X one-year expected designed from In Phase to trial an PFS in care assess XXXX. the cancer tumor we the Enrollment radiation. combination checkpoint lung assessing inhibitors, development chemo to Cancer with non-small two patients non-squamous Stage in by inhibitor endpoint begin continues in initiated detect treatment TRCXXX results our of and repair year the this damage fall DNA randomized The Institute in to to TRCXXX. trials XX%. expected addition standard radiation XX cell X a fund to are In the primary February therapy trial's PFS at trial NCI The enroll and or the will
that a a with and X TRACON CDXX Our evaluating in is agent tri-centric. asset stage single fourth TJXXXX inhibitor clinical as the is in checkpoint Phase a antibody combination study
We patient. to the which analysis the data are working last trial, complete enrolled has of
the provide Phase terminate Next, As completion state legal on X partner, with our a a payment I the two update license to of agreement TJXXXX disputes, are indicated of TRACON to that the I-Mab reminder, the Fifth, terminate will desire which corporate desire trial for option has exercise arbitration a of I-Mab. for their in $X a million. of their to following payment
heard both before of for our February International an Chamber Law. of Arbitral in under of As were license alleged agreements Tribunal a reminder New arguments I-Mab this York Commerce with breaches year
release past issued for KG to first Asian, TRACON As million payments believe a license, exclusive countries XXXX, I-Mab $XXX negotiation under to a to based Eastern potential Bio. in partnership KG described African that receive right press and in strategic with entitled on a payment Bio We I-Mab. announcing at multiple of time received that we've as the a with Middle the agreement. to in release noted TJXXXX March was in Bio commercialize up Whereby TJXXXX press the KG a for rights
Although I-Mab payment is this disputed due. that has
regards proceeded I-Mab collaboration agreement XXXX Bispecific license November XXXX. issues agreements with I-Mab ABL with The with other dispute I-Mab's Antibody that in disputes and them. to in Agreement The in July agreement two include our related Bio this our with
their to terms obligations the year. the agreement As the TJXXXX and Pending post disputes results this continue of to of hearing later of expect the Antibody consideration we agreements. by under under Bispecific decision binding we Agreement remain and our meet both been arbitration have guided today, tribunal,
provide their an We promptly announce update findings. the tribunal when will panel
corporate Given be is through development we product most from supplemented organizations. enabled further may development one makes capital to important expectation our non-dilutive capital for opportunities us non-dilutive that clinical the markets, by efficient secure believe partner challenging capital platform, and the our of the CRO-independent
in to to TRACON. leverage expect to capital non-dilutive that two continue potential our platform for ways We provide
in share drug Johnson. evaluating our a to from fees clinical whereby TRACON royalties the are costs. in Johnson is including premium structure performs sublicensing we revenue, And or This example a with used past First, commercialization. candidates an then the TRACON & and aligned at we trials for earns
are we with companies clinical paid franchise use to whereby knowhow capabilities we share are these to to trials. operations a contracting to our avoid exploring other proprietary clinical independently new internalize enable model capabilities to and Second, execute and CROs
As provide in the such substantial quality reap been partner. over CRO-independent compelling trials would contracted an wish cost time and At product an at the We to higher our result at TRACON of for on expected CROs. a this experience platforms financials. who companies our has lower to strong will typically credibility those time, our be costs than rewards are update trials investment in faster as believe therefore for and development that time, become solution conducting Scott savings and
